PD2-4 Survival Advantage of Temsirolimus Validates a Role for Mammalian Target of Rapamycin (mTOR) in the Biology of Advanced Renal Cell Carcinoma
Year: 2008
Type: article
Abstract: Temsiroiimus, a specific inhibiter of mTOR, is a novel targeted therapy for the treatment of advanced renal cell carcinoma (RCC).In preclinical models, mTOR
Source: The Japanese Journal of Urology
Author: Robert A. Figlin
Institutions: City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W438392113